Inherited Skin Disorders
The EB Haus Study Centre in Salzburg is involved in clinical research focused on recessive dystrophic epidermolysis bullosa, a severe inherited condition marked by fragile skin and chronic wound burden.
- Recessive dystrophic epidermolysis bullosa
- Skin fragility disorders
- Chronic wound complications
This area reflects a clinical interest in the dermatologic and tissue-healing challenges associated with rare genetic blistering diseases.
Cutaneous Oncology
The sponsor also supports research in locally advanced and metastatic squamous cell carcinoma arising in the setting of epidermolysis bullosa, with attention to aggressive skin cancer behavior.
- Squamous cell carcinoma
- Locally advanced disease
- Metastatic disease
Its therapeutic focus includes malignancies that develop on chronically damaged skin and require specialized oncologic care.
Rare Disease Therapeutics
Clinical activity at the centre includes evaluation of treatments for rare disease populations, with emphasis on conditions where standard options are limited and unmet medical need remains high.
- Rare disease treatment
- Unmet medical need
- Specialized supportive care
This research setting links dermatology and oncology within a rare-disease framework.
Anticancer Drug Evaluation
The sponsor is engaged in assessment of an antineoplastic agent for patients with advanced skin cancer, with clinical interest in tolerability and tumor control in a difficult-to-treat population.
- Antineoplastic therapy
- Tumor response assessment
- Advanced cancer care
This area aligns with efforts to expand treatment options for patients affected by rare, aggressive cutaneous malignancies.
